Drug intelligence / Profile preview

MGB-005

Development stage: Preclinical
Lead developer: MetaGen Biologics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MGB-005 is a biosimilar monoclonal antibody candidate being developed by MetaGen Biologics. It targets the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), an immune checkpoint molecule that downregulates T-cell activation. By binding to CTLA-4, MGB-005 blocks its interaction with ligands CD80/CD86, thereby enhancing T-cell-mediated anti-tumor immune responses. It is being developed as a biosimilar to the reference product Yervoy (ipilimumab), with a primary focus on the treatment of melanoma. As of the latest pipeline updates, the drug is in the preclinical stage of development.

Other names: ipilimumab biosimilar

Targets

CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)

Beyond the preview

Go deeper on MGB-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MGB-005.

Explore the full profile